AST2818 in Advanced Non-Small Cell Lung Cancer With EGFR Mutations

Updated 06/21/2024

Status Active, not recruiting

Clinical Trial Summary

This study is conducted to assess the safety, tolerability and preliminary efficacy of AST2818 in patients with advanced Non Small Cell Lung Cancer (NSCLC).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03127449
Study type	Interventional
Source	Allist Pharmaceuticals, Inc.
Contact
Status	Active, not recruiting
Phase	N/A
Start date	June 1, 2017
Completion date	December 2020

See also
	Status	Clinical Trial	Phase
	Recruiting	`NCT02133196` - T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer	Phase 2
	Recruiting	`NCT00813332` - Second-line Therapy Study of Combined Chemotherapy and Endostar to Patients With Non-Small Cell Lung Cancer(NSCLC)	Phase 4
	Completed	`NCT03215810` - Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer	Phase 1
	Recruiting	`NCT04982224` - Study of REGN5093-M114 (METxMET Antibody-Drug Conjugate) in Adult Patients With Mesenchymal Epithelial Transition Factor (MET) Overexpressing Advanced Cancer	Phase 1/Phase 2
	Recruiting	`NCT05609578` - Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation	Phase 2
	Not yet recruiting	`NCT04992858` - Ningetinib in Advanced NSCLC Skipping Mutations With MET Exon 14 Skipping Mutations	Phase 2
	Not yet recruiting	`NCT06356675` - A Single-arm Pilot Study of Tislelizumab Combined With Anlotinib in Patients With Advanced NSCLC With Driver-negative After Progression to Immunotherapy	Phase 4
	Completed	`NCT03074175` - Plasma miRNAs Predict Radiosensitivity of Different Fractionation Regimes in Palliative Radiotherapy for Advanced Non-small Cell Lung Cancer：Multicenter Controlled Study.(RadmiR-01)	N/A
	Terminated	`NCT05106335` - A Study to Evaluate Camrelizumab Combined With Famitinib as Subsequent Therapy in Patients With Advanced NSCLC	Phase 3
	Not yet recruiting	`NCT04229121` - Clinical Sensitivity Verification Study of Circulating Tumor Cells Gene Mutation Detection From Advanced NSCLC Patients
	Completed	`NCT05219162` - Real-World Study on Gene Profile in Patients With Advanced NSCLC Who Progressed on First-Line Osimertinib Therapy(GPS).	Phase 4
	Not yet recruiting	`NCT05859217` - A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1)	Phase 2
	Recruiting	`NCT03062800` - Study of Thalidomide in Treatment of Advanced Nsclc (Dream-003)	Phase 2
	Completed	`NCT02055508` - POSITIVE - Study (Part III) Heidelberg	N/A
	Active, not recruiting	`NCT04043195` - Nivolumab and Ipilimumab in Combination With Immunogenic Chemotherapy for Patients With Advanced NSCLC	Phase 1/Phase 2